<DOC>
	<DOCNO>NCT01827839</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GSK Biologicals ' HZ/su vaccine subject ' ≥ 50 year age ( YOA ) previously Herpes Zoster ( HZ ) . The data collect compare data subject without HZ HZ/su trial .</brief_summary>
	<brief_title>Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster Subunit ( HZ/su ) Vaccine GSK1437173A Adults With Prior Episode Herpes Zoster</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects physiciandocumented history HZ . Subjects , opinion investigator , comply requirement protocol . A male female age 50 year old time first vaccination . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Active Herpes Zoster infection ( case consider active lesion least turned crust ) . Use investigational nonregistered product study vaccine/product within 30 day precede first dose study vaccine/product , plan use study period . Chronic administration ( defined &gt; 14 consecutive day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , prednisone dose &lt; 20 mg/day , equivalent , allow . Inhaled , topical intraarticular corticosteroid allow . Administration longacting immunemodifying drug within six month prior first vaccine dose expect administration time study period . Administration plan administration live vaccine period start 30 day first dose study vaccine end 30 day last dose study vaccine , , administration plan administration nonreplicating vaccine within 8 day prior within 14 day either dose study vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Previous vaccination VZV HZ and/or plan administration study HZ vaccine study vaccine . Any confirm suspected immunosuppressive immunodeficient condition result disease immunosuppressive/cytotoxic therapy . History reaction hypersensitivity likely exacerbate component vaccine/product . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any condition , judgment investigator , would make intramuscular injection unsafe . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution Month 4 ( i.e . 2 month last dose study vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adults</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Zoster</keyword>
</DOC>